In This Article:
Every investor in Suven Life Sciences Limited (NSE:SUVEN) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.
Suven Life Sciences is not a large company by global standards. It has a market capitalization of ₹37b, which means it wouldn't have the attention of many institutional investors. In the chart below below, we can see that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholder can tell us about SUVEN.
View our latest analysis for Suven Life Sciences
What Does The Institutional Ownership Tell Us About Suven Life Sciences?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors own 7.7% of Suven Life Sciences. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Suven Life Sciences's earnings history, below. Of course, the future is what really matters.
We note that hedge funds don't have a meaningful investment in Suven Life Sciences. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Suven Life Sciences
The definition of company insiders can be subjective, and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Shareholders would probably be interested to learn that insiders own shares in Suven Life Sciences Limited. As individuals, the insiders collectively own ₹1.3b worth of the ₹37b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public holds a 28% stake in SUVEN. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.